Vertex Puts up $375M for ViroChem, Nuance Finally Nabs Zi, Proteon Procures $38M, & More Boston-Area Deals News
Summary
—Ariad Pharmaceuticals (NASDAQ: ARIA) of Cambridge, MA, earned a $10 million milestone payment from its partner, Merck, as part of an existing deal between the firms focused on Ariad’s experimental drug for lung cancer. —Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ:VRTX) inked a deal to acquire privately held ViroChem Pharma of Laval, Quebec, for some $375 million in cash and stock. —Westford, MA-based Verivue, a maker of cross-platform video streaming technology, revealed it had raised $40 million in a Series B financing round closed last July. —Waltham, MA-based Onset Technology, a provider of compliance software for smartphones, raised $3 million in a financing led by the Cedar Fund of Waltham, Israel, and Grand Cayman. Proteon’s lead product candidate is a protein drug designed to improve the outcome of a surgery that prepares kidney disease patients’ blood vessels to be frequently hooked up to dialysis machines.
